Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

NAL ER

Phase 2Small molecule

TTrevi Therapeutics

1

Indications

8

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Refractory Chronic CoughRecruiting

Refractory Chronic CoughPhase 2

Recruiting

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Refractory Chronic Cough

NCT07671924

Q3 2028

Phase 3Recruiting

Idiopathic Pulmonary Fibrosis

NCT07671911

Clinical

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis4 trials

A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough

Completed·TTrevi Therapeutics·Phase 2·NCT04030026·42 enrolled

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Chronic Cough in Participants With Idiopathic Pulmonary Fibrosis

Recruiting·TTrevi Therapeutics·Phase 3·NCT07671911·306 enrolled

An Open Label, In-Clinic Study to Assess Respiratory Function and Safety of Escalating Doses of Nalbuphine Extended-Release Tablets (NAL ER) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Completed·TTrevi Therapeutics·Phase 1·NCT07036029·9 enrolled

Show 1 more trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)

Completed·TTrevi Therapeutics·Phase 2·NCT05964335·165 enrolled

Chronic Cough1 trial

Refractory Chronic Cough Improvement Via NAL ER (RIVER)

Completed·TTrevi Therapeutics·Phase 2·NCT05962151·66 enrolled

Interaction1 trial

A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants

Completed·TTrevi Therapeutics·Phase 1·NCT07015398·132 enrolled

Refractory Chronic Cough1 trial

A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Participants With Refractory Chronic Cough

Recruiting·TTrevi Therapeutics·Phase 2·NCT07671924·100 enrolled

Unspecified1 trial

A Randomized, Phase 1, Open-Label, Two-Treatment, Two- Period, Two-Sequence, Single-Dose Crossover Study to Evaluate the Effect of Food on the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Subjects

Completed·TTrevi Therapeutics·Phase 1·NCT07487740·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for NAL ER. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NAL ER compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NAL ER. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Trevi Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTrevi Therapeutics

Related News